Baxter International
VC Fund
Deerfield, United States
Baxter International is a VC fund in Deerfield focused on Health Care and Biotechnology. Baxter International Inc. develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.The company operates through three segments: BioScience, Medication Delivery, and Renal.- The BioScience segment manufacturesrecombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha 1-antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; products for regenerative medicine, such as biosurgery products and technologies used in adult stem-cell therapies; and vaccines.- The Medication Delivery segment manufactures intravenous solutions and administration sets; premixed drugs and drug-reconstitution systems; pre-filled vials and syringes for injectable drugs, intravenous nutrition products; infusion pumps; and inhalation anesthetics. This segment also offers products and services related to pharmacy compounding, drug formulation, and packaging technologies.- The Renal segment provides products to treat end-stage renal disease and irreversible kidney failure. This segment also offers solutions and other products for peritoneal dialysis, a home-based therapy and product for hemodialysis, which is conducted in a hospital or clinic.Baxter International Inc. has collaborations with HHD LLC, DEKA Products Limited Partnership, and DEKA Research and Development Corp. for the development of a home hemodialysis machine. It markets its products to hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors offices, clinical and medical research laboratories, and patients at home under physician supervision.The company was founded in 1931 and is headquartered in Deerfield, Illinois.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Baxter International invests in
Stages Baxter International invests in
Countries Baxter International invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $238k–$1.5M
- Series C
- $3.3M–$25M
Investment Focus
Industry
- Health Care 6 (67%)
- Biotechnology 5 (56%)
- Medical 3 (33%)
- Medical Device 3 (33%)
- Biopharma 2 (22%)
Stage
- Seed 2 (22%)
- Series B 2 (22%)
- Series C 2 (22%)
- Series A 1 (11%)
- Series D 1 (11%)
Country
- United States 5 (56%)
- Canada 1 (11%)
- Austria 1 (11%)
- Ireland 1 (11%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Ellen McIntosh
SVP, Associate General Counsel
|
SVP, Associate General Counsel | Total investments: 0 | Find email | |
David Ferguson
General Manager, Medication Delivery Global Business Unit
|
General Manager, Medication Delivery Global Business Unit | Total investments: 0 | Find email | |
David Roman
Vice President, Strategy & FP&A
|
Vice President, Strategy & FP&A | Total investments: 0 | Find email | |
Dennis Crowley
SVP Business Development & Licensing
|
SVP Business Development & Licensing | Total investments: 1 | Find email | |
Giuseppe Accogli
SVP & President Global Businesses
|
SVP & President Global Businesses | Total investments: 1 | Find email | |
| See all 11 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
NovaXS Biotech
|
NovaXS is developing the next generation of smart needle-free drug delivery platform that improves the medication adherence and optimizes the treatment outcomes. | $1.5M / Seed / Mar 15, 2022 | |
Medically Home
|
Medically Home is a tech-enabled clinical enterprise that provides all the necessary capabilities to safely-shift medical care from hospitals to patients’ homes. Its platform offers a virtual hospital program that connects patients with caregivers and supports the monitoring of, and communication with patients with high acuity illness that helppatients and their families to access a medical command center that provides centralized, on-demand acute medical care management from the comfort of their homes.The company was founded in 2016 and is headquartered in Boston, Massachusetts. | $110M / Venture - Series Unknown / Jan 10, 2022 | |
Walela
|
Walela is a medical device company that develops sensor technology to improve fetal and maternal outcomes. It measures fetal heart rate and blood pH using its specialized medical technology. The company was founded by James Balman in 2021 and is headquartered in Chicago, Illinois. | $237.5K / Seed / Nov 21, 2021 | |
Ayogo Health
|
Ayogo is a global leader in the application of behavioral psychology and social gaming to improve health outcomes for patients. Healthier patients improve financial outcomes. Insurers, healthcare providers, ACOs and pharmaceutical companies are Ayogo’s clients. All of our projects begin with meaningful collaboration with patients, end-users andclients. Our corporate culture fosters excellence and thoughtful creation. We maintain the open culture of a startup at our studio in Vancouver’s Centre for Digital Media where our software engineers, user-experience designers, artists and other experts in patient engagement work together. | $7.5M / Series B / May 01, 2020 | |
Naurex
|
Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR). Using these discoveries, Naurex researchers have generated novel chemical drug classes known as glycine-site functional partial agonists (GFPAs),which modulate the receptor in a different way than existing NMDAR agents. The company's drug development programs based on its GFPA NMDAR modulators include the first-generation molecule, GLYX-13, the second-generation NRX-1050 small molecule series and additional compounds from Naurex's platform of novel NMDAR modulators. | $25M / Series C / May 06, 2014 | |
Opsona
|
Drug development firm focused on immunology. They are headquartered in Dublin, Ireland. Opsona Therapeutics is one of Europe's most innovative and dynamic drug development companies. We are at the forefront of drug development in immunology research, with particular focus on the innate immunity pathways. Since its founding in 2004,Opsona has validated and developed a series of exciting new drug candidates and strategies which modulate the human innate immune system. We are located in Dublin, Ireland. | $3.3M / Series C / Oct 02, 2013 | |
Ocular Therapeutix
|
Ocular Therapeutix, Inc. engages in the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. Its products include ReSure Adherent Ocular Bandage, a synthetic ocular bandage for ophthalmic surgery; ReSure Sealant, a synthetic andbiocompatible hydrogel that creates a temporary, soft, and lubricious surface barrier to protect clear corneal incisions in the immediate post-operative period; and prostaglandin analog punctum plugs that are hydrogel-based punctum plug depots to deliver prostaglandin analogs to treat glaucoma. | $23.8M / Series D / Jun 10, 2013 | |
Zytoprotec
|
Zytoprotec is an Austrian biotechnology company, founded in 2007 to apply ground-breaking findings in the area of cytoprotection to the development of new treatment options for major disease areas.The Company was founded by a team of professionals that combine extensive experience in business administration, clinical research, pharmaceuticalproduct development, as well as company and patent law. | $2.2M / Series A / Jan 29, 2013 | |
|
Naurex
|
Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR). Using these discoveries, Naurex researchers have generated novel chemical drug classes known as glycine-site functional partial agonists (GFPAs),which modulate the receptor in a different way than existing NMDAR agents. The company's drug development programs based on its GFPA NMDAR modulators include the first-generation molecule, GLYX-13, the second-generation NRX-1050 small molecule series and additional compounds from Naurex's platform of novel NMDAR modulators. | $38M / Series B / Dec 17, 2012 |
Co-Investors
Mayo Clinic
3 deals together
7wire Ventures
2 deals together
Cardinal Health
2 deals together
Edward-Elmhurst Health
2 deals together
mHUB
2 deals together
Adams Street Partners
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Baxter International invest in?
Baxter International invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Series B stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Baxter International's check size?
Baxter International typically joins rounds of $238k–$1.5M at Seed and $3.3M–$25M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Baxter International participates in.
How do I contact Baxter International?
Public channels for Baxter International include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Baxter International?
The team at Baxter International includes Ellen McIntosh (SVP, Associate General Counsel), David Ferguson (General Manager, Medication Delivery Global Business Unit) and David Roman (Vice President, Strategy & FP&A), among 11 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
